Your browser is no longer supported. Please, upgrade your browser.
Bellicum Pharmaceuticals, Inc.
Index- P/E2.39 EPS (ttm)0.86 Insider Own0.59% Shs Outstand10.11M Perf Week-20.38%
Market Cap17.99M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float8.35M Perf Month-30.42%
Income4.40M PEG- EPS next Q- Inst Own23.80% Short Float9.66% Perf Quarter-27.62%
Sales1.20M P/S14.99 EPS this Y94.40% Inst Trans- Short Ratio2.66 Perf Half Y-35.51%
Book/sh-1.41 P/B- EPS next Y- ROA11.30% Target Price- Perf Year-66.18%
Cash/sh- P/C- EPS next 5Y- ROE-22.80% 52W Range2.20 - 8.15 Perf YTD-41.36%
Dividend- P/FCF- EPS past 5Y40.80% ROI2063.20% 52W High-74.60% Beta1.69
Dividend %- Quick Ratio1.20 Sales past 5Y12.10% Gross Margin- 52W Low-5.91% ATR0.16
Employees16 Current Ratio1.20 Sales Q/Q- Oper. Margin- RSI (14)21.35 Volatility8.43% 5.65%
OptionableNo Debt/Eq- EPS Q/Q97.50% Profit Margin- Rel Volume0.90 Prev Close2.23
ShortableYes LT Debt/Eq- Earnings- Payout0.00% Avg Volume303.51K Price2.07
Recom3.00 SMA20-23.49% SMA50-28.49% SMA200-40.11% Volume274,180 Change-7.17%
Oct-30-20Downgrade Wells Fargo Overweight → Equal Weight $4.50
Oct-30-20Downgrade Ladenburg Thalmann Buy → Neutral
Apr-12-18Upgrade Wells Fargo Market Perform → Outperform
Apr-12-18Reiterated Cantor Fitzgerald Overweight $10 → $18
Jan-31-18Reiterated Cantor Fitzgerald Overweight $12 → $10
Jan-31-18Downgrade Wells Fargo Outperform → Market Perform
Mar-08-17Initiated Wells Fargo Outperform
Dec-01-16Initiated Raymond James Outperform
Nov-30-16Initiated Ladenburg Thalmann Buy
Nov-02-16Initiated Cantor Fitzgerald Buy $32
Aug-09-16Upgrade Citigroup Neutral → Buy
Feb-25-16Initiated Citigroup Neutral $11
Sep-11-15Upgrade Guggenheim Neutral → Buy
Jul-24-15Initiated Citigroup Buy
Sep-03-21 07:30AM  
Sep-01-21 12:00PM  
Aug-12-21 04:05PM  
Jul-26-21 05:25PM  
Jun-28-21 07:30AM  
Jun-13-21 02:11PM  
May-17-21 07:30AM  
Mar-30-21 04:05PM  
Mar-23-21 04:05PM  
Mar-04-21 08:39AM  
Feb-08-21 08:30AM  
Jan-28-21 04:05PM  
Jan-07-21 08:19AM  
Jan-06-21 08:43AM  
Dec-25-20 12:00PM  
Dec-18-20 07:39AM  
Dec-10-20 07:30AM  
Dec-07-20 07:47AM  
Nov-27-20 04:12PM  
Nov-25-20 10:31AM  
Nov-20-20 12:00PM  
Nov-19-20 07:41AM  
Nov-05-20 04:05PM  
Nov-03-20 08:26PM  
Oct-30-20 01:03PM  
Oct-29-20 05:16PM  
Sep-30-20 04:07PM  
Sep-28-20 07:30AM  
Sep-18-20 11:31AM  
Sep-02-20 07:30AM  
Aug-31-20 04:07PM  
Aug-06-20 04:05PM  
Jul-31-20 04:08PM  
Jul-30-20 04:05PM  
Jun-15-20 07:30AM  
Jun-12-20 10:44AM  
Jun-03-20 09:00AM  
Jun-01-20 10:45AM  
May-29-20 04:06PM  
May-27-20 04:05PM  
May-22-20 12:00PM  
May-07-20 04:05PM  
May-06-20 10:29AM  
Apr-30-20 04:09PM  
Apr-17-20 02:44PM  
Apr-15-20 07:30AM  
Mar-31-20 10:55AM  
Mar-12-20 04:05PM  
Mar-10-20 06:48AM  
Mar-05-20 07:30AM  
Mar-03-20 12:30PM  
Feb-28-20 04:08PM  
Feb-07-20 09:42AM  
Feb-05-20 12:45PM  
Feb-02-20 07:00AM  
Jan-31-20 04:05PM  
Jan-25-20 09:25AM  
Jan-24-20 07:30AM  
Jan-22-20 09:33AM  
Jan-21-20 07:30AM  
Jan-16-20 07:30AM  
Dec-13-19 02:45PM  
Dec-11-19 07:30AM  
Dec-10-19 06:42AM  
Nov-22-19 10:50PM  
Nov-17-19 07:14AM  
Nov-08-19 07:00AM  
Nov-06-19 07:15PM  
Oct-31-19 04:05PM  
Oct-30-19 07:30AM  
Oct-29-19 10:33AM  
Oct-26-19 08:57AM  
Sep-30-19 04:07PM  
Sep-23-19 10:54AM  
Sep-03-19 02:53PM  
Aug-30-19 04:08PM  
Aug-28-19 04:05PM  
Aug-21-19 04:05PM  
Aug-20-19 03:47PM  
Aug-16-19 10:56AM  
Aug-15-19 05:37PM  
Aug-05-19 06:15PM  
Jul-30-19 10:38AM  
Jul-19-19 07:32AM  
Jul-08-19 08:00AM  
Jun-13-19 11:53AM  
Jun-01-19 09:00AM  
Bellicum Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. The company's clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing the prostate stem cell antigen; and BPX-603, a dual-switch GoCAR-T product candidate that is in Phase 1/2 clinical trials to treat solid tumors that express the human epidermal growth factor receptor 2 antigens. Its clinical product candidates also include Rivo-cel, an allogeneic T cell product candidate intended to enhance outcomes when administered after hematopoietic stem cell transplantation in the treatment of hematologic malignancies and inherited blood disorders. It has collaboration and license agreements with Adaptimmune Therapeutics plc; Agensys, Inc.; BioVec Pharma, Inc.; ARIAD Pharmaceuticals, Inc.; and Baylor College of Medicine. Bellicum Pharmaceuticals, Inc. was incorporated in 2004 and is based in Houston, Texas.